Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chongqing Taiji Industry (Group) Co (SHSE:600129) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Chongqing Taiji Industry (Group) Co's Enterprise Value for the quarter that ended in Jun. 2026 was ¥12,398 Mil.
Chongqing Taiji Industry (Group) Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥302 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chongqing Taiji Industry (Group) Co EV-to-EBIT Related Terms
Chongqing Taiji Industry (Group) Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chongqing Taiji Industry (Group) Co EV-to-EBIT Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Chongqing Taiji Industry (Group) Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chongqing Taiji Industry (Group) Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Chongqing Taiji Industry (Group) Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Chongqing Taiji Industry (Group) Co's EV-to-EBIT falls into.
Chongqing Taiji Industry (Group) Co's current Enterprise Value is ¥12,718 Mil.
Chongqing Taiji Industry (Group) Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥302 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chongqing Taiji Industry (Group) Co (SHSE:600129) has a EV-to-EBIT of 42.13 as of Sep. 02, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Chongqing Taiji Industry (Group) Co and its competitors. This is 76% above median its historical median of 23.92. According to the industry distribution chart, Chongqing Taiji Industry (Group) Co ranks #544 out of 683 companies in the Drug Manufacturers industry, placing it in the top 79.6%.
Is Chongqing Taiji Industry (Group) Co's EV-to-EBIT too high?
Chongqing Taiji Industry (Group) Co's current EV-to-EBIT of 42.13 is 76% above median its 10-year median of 23.92. The Drug Manufacturers industry median EV-to-EBIT is 16.09. Chongqing Taiji Industry (Group) Co's value of 42.13 is 161.8% above this industry median. Based on the distribution chart, Chongqing Taiji Industry (Group) Co ranks #544 out of 683 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Chongqing Taiji Industry (Group) Co has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Chongqing Taiji Industry (Group) Co's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Chongqing Taiji Industry (Group) Co ranks #544 out of 683 companies for EV-to-EBIT. This places Chongqing Taiji Industry (Group) Co in the lower half of its industry. The industry median EV-to-EBIT is 16.09. Chongqing Taiji Industry (Group) Co's value of 42.13 is 161.8% above this benchmark. While the company's 10-year median is 23.92 vs. the industry median of 16.09, Chongqing Taiji Industry (Group) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.09, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chongqing Taiji Industry (Group) Co's current EV-to-EBIT of 42.13 is 161.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Chongqing Taiji Industry (Group) Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chongqing Taiji Industry (Group) Co's current EV-to-EBIT is 42.13, which is 76% above median its own 10-year median of 23.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chongqing Taiji Industry (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Chongqing Taiji Industry (Group) Co (SHSE:600129) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥19.46, compared to a current price of ¥13.90 — trading 28.6% below its estimated fair value. The current EV-to-EBIT is 42.13, which is 76% above median its 10-year median of 23.92 and 161.8% above the Drug Manufacturers industry median of 16.09. Chongqing Taiji Industry (Group) Co's overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Chongqing Taiji Industry (Group) Co (SHSE:600129), the current EV-to-EBIT is 42.13 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chongqing Taiji Industry (Group) Co (SHSE:600129) Overvalued in 2026?
Based on GuruFocus' analysis, Chongqing Taiji Industry (Group) Co stock appears to be undervalued.
The current stock price of ¥13.90 is trading 28.6% below its estimated GF Value™ of ¥19.46.
GuruFocus considers Chongqing Taiji Industry (Group) Co to be Modestly Undervalued.
Key valuation signals for SHSE:600129:
EV-to-EBIT: 42.13 (76% above median its 10-year median of 23.92)
GF Value™: ¥19.46 vs. price of ¥13.90 (28.6% below fair value)
Industry Position: 161.8% above the Drug Manufacturers median (#544 of 683)
No single metric tells the full story. See the SHSE:600129 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chongqing Taiji Industry (Group) Co Ltd is a China-based company engaged in the production and sales of Chinese and Western medicines. It is also engaged in the cultivation of medicinal herbs. Its products mainly include capsules, syrup, oral liquid, lyophilized series, tablets, infusion series, and injections. The company mainly conducts its business in domestic and overseas markets.
73GF Score
Get the complete analysis for SHSE:600129
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600129 has been successfully added to your 
